HUT44941A - Process for producing stabile pharmaceutical compositions containing stimulating factor for colonies of granulocites - Google Patents

Process for producing stabile pharmaceutical compositions containing stimulating factor for colonies of granulocites

Info

Publication number
HUT44941A
HUT44941A HU873268A HU326887A HUT44941A HU T44941 A HUT44941 A HU T44941A HU 873268 A HU873268 A HU 873268A HU 326887 A HU326887 A HU 326887A HU T44941 A HUT44941 A HU T44941A
Authority
HU
Hungary
Prior art keywords
granulocites
colonies
pharmaceutical compositions
compositions containing
stimulating factor
Prior art date
Application number
HU873268A
Other languages
Hungarian (hu)
Other versions
HU198627B (en
Inventor
Minoru Machida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of HUT44941A publication Critical patent/HUT44941A/en
Publication of HU198627B publication Critical patent/HU198627B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
HU873268A 1986-07-18 1987-07-17 Process for producing stable pharmaceutical composition comprising granulocyte colony stimulating factor HU198627B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948986 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18

Publications (2)

Publication Number Publication Date
HUT44941A true HUT44941A (en) 1988-05-30
HU198627B HU198627B (en) 1989-11-28

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
HU873268A HU198627B (en) 1986-07-18 1987-07-17 Process for producing stable pharmaceutical composition comprising granulocyte colony stimulating factor

Country Status (24)

Country Link
KR (1) KR930004597B1 (en)
CN (1) CN1033738C (en)
AT (1) AT402259B (en)
AU (1) AU611856B2 (en)
BE (1) BE1000253A3 (en)
CA (1) CA1297007C (en)
CH (1) CH671157A5 (en)
DE (1) DE3723781C2 (en)
DK (1) DK171308B1 (en)
ES (1) ES2010226A6 (en)
FR (1) FR2601591B1 (en)
GB (1) GB2193631B (en)
GR (1) GR871067B (en)
HK (1) HK64893A (en)
HU (1) HU198627B (en)
IE (1) IE60290B1 (en)
IL (1) IL83220A (en)
IT (1) IT1218927B (en)
NL (1) NL192917C (en)
NO (1) NO171828C (en)
PT (1) PT85343B (en)
SE (1) SE503312C2 (en)
SG (1) SG64393G (en)
YU (1) YU47543B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP3249147B2 (en) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2693907B1 (en) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa A method of administering granulocyte colony stimulating factor solutions.
EP0582932A1 (en) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutic system for the parenteral administration of hematopoietic growth factors
DE4242919A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Process for the preparation of storage-stable aqueous pharmaceutical preparations of G-CSF
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP3895109B2 (en) * 1998-03-06 2007-03-22 中外製薬株式会社 Protein-free formulation
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
TWI245645B (en) * 1999-09-08 2005-12-21 Chugai Pharmaceutical Co Ltd Protein solution formulations and stabilization methods thereof
TR200401573T4 (en) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
WO2001064241A1 (en) * 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530839A (en) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション Albumin fusion protein
AU2001282607B2 (en) * 2000-09-01 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Solution preparations stabilized over long time
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
EP1541585B1 (en) 2002-08-27 2013-01-30 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
DE202006020194U1 (en) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF liquid formulation
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
RU2519031C1 (en) 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Liquid formulations for long-acting conjugate of g-csf
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
KR20210089270A (en) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 Compositions and methods for treating cancer
BR112018016924A2 (en) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd treatment regimen selection method for individual who has acute myeloid leukemia (LMA), acute response myeloid leukemia (LMA) treatment maximization method, lma treatment method, cxcr4 antagonist, and chemotherapeutic agent in the treatment of lma
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
EP3797752A4 (en) * 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass vial

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (en) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Stabilising protein during separation, purification and storage - by adding amphiphilic cpds., esp. lipid(s), ionic and or nonionic detergents
SE451844B (en) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd GLYCOPROTEIN, PROCEDURE FOR PREPARING THEREOF AND THERAPEUTIC AGENTS INCLUDING THE GLYCOPROTEIN
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS61227526A (en) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
JPS6191131A (en) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd Method and composition for preventing adsorption of pharmaceutical
DE3686794T2 (en) * 1985-02-05 1993-03-04 Cetus Oncology Corp CLEANING THE NATURAL COLONY-STIMULATING FACTOR-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (en) * 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment

Also Published As

Publication number Publication date
BE1000253A3 (en) 1988-09-27
SE8702907L (en) 1988-01-19
IE60290B1 (en) 1994-06-29
IL83220A (en) 1993-01-31
DK171308B1 (en) 1996-09-02
DK368387D0 (en) 1987-07-15
ATA177587A (en) 1996-08-15
PT85343A (en) 1987-08-01
FR2601591B1 (en) 1991-04-26
SG64393G (en) 1993-08-06
AU7566587A (en) 1988-01-21
GB2193631B (en) 1990-11-21
NL192917C (en) 1998-05-07
ES2010226A6 (en) 1989-11-01
HK64893A (en) 1993-07-16
NO171828B (en) 1993-02-01
AT402259B (en) 1997-03-25
SE8702907D0 (en) 1987-07-17
DE3723781A1 (en) 1988-01-21
IE871933L (en) 1988-01-18
YU47543B (en) 1995-10-03
DE3723781C2 (en) 1999-09-02
PT85343B (en) 1990-04-30
IL83220A0 (en) 1987-12-31
GB2193631A (en) 1988-02-17
CN1033738C (en) 1997-01-08
DK368387A (en) 1988-01-19
FR2601591A1 (en) 1988-01-22
AU611856B2 (en) 1991-06-27
NO872966D0 (en) 1987-07-16
CN87104963A (en) 1988-02-24
IT8767594A0 (en) 1987-07-10
NL192917B (en) 1998-01-05
IT1218927B (en) 1990-04-24
YU134287A (en) 1989-06-30
NO872966L (en) 1988-01-19
KR880001297A (en) 1988-04-22
CA1297007C (en) 1992-03-10
KR930004597B1 (en) 1993-06-01
NL8701640A (en) 1988-02-16
GB8716904D0 (en) 1987-08-26
SE503312C2 (en) 1996-05-13
NO171828C (en) 1993-05-12
GR871067B (en) 1987-11-19
CH671157A5 (en) 1989-08-15
HU198627B (en) 1989-11-28

Similar Documents

Publication Publication Date Title
HUT44941A (en) Process for producing stabile pharmaceutical compositions containing stimulating factor for colonies of granulocites
HUT47561A (en) Process for production of 3-aryloxi-3-substituated propanamids and medical compositions containing them
HUT45895A (en) Process for production of serotomin antagonic compounds and medical preparatives containing such compositions
HUT47568A (en) Process for production of derivatives of tiazepine and medical compositions containing them
HUT47022A (en) Process for production of medical compositions
HUT50190A (en) Process for production of n-substituated 1-dezoxinogimiricin and 1-dezoxi-manno-nogimiricin and medical compositions containing them
HUT46221A (en) Process for production of medical compositions containing alphusosine
HUT50151A (en) Process for production of benzo/b/pirans and piranpiridins and medical compositions containing them
HUT42953A (en) Process for production of medical compositions
HUT40759A (en) Process for production of medical preparatives containing derivatives of antracyclin-glycosid
HUT49893A (en) Process for production of new crystallic formation and medical compositions containing it
HUT45894A (en) Process for production of shaped medical plaster
HUT37354A (en) Process for production of medical plaster
HUT45982A (en) Process for production of microlide compositions and medical preparatives containing such compositions
HUT45979A (en) Process for production of 5-phenil-2-oxasole-derivatives and medical compositions containing such compounds
HUT50166A (en) Process for production of substituated 3,4-dihydro-rh-benzopiranes and medical compositions containing them
HUT51247A (en) Process for production of aryl-zyanguananidins and medical compositions containing them
HUT47267A (en) Process for production of new pirasoline-derivatives and medical compositions containing them
HUT50165A (en) Process for production of alkyl substituated n-benzopiramil lactanes and medical compositions containing them
HUT50167A (en) Process for production of derivatives of tetrasole and medical compositions containing them
HUT47594A (en) Process for production of new derivatives of furanuronic acid and medical compositions containing them
HUT45968A (en) Process for production of derivatives of substituated amin and medical compositions containing these compounds
HUT39142A (en) Process for producing naphtyl-analogues of mevalolactone and derivatives and pharmaceutical compositions containing them
HUT42455A (en) Process for production of derivatives of 5-substituated amino-piramidin and medical compositions containing thereof
HU886797D0 (en) Process for production of medical compositions against caries of bones

Legal Events

Date Code Title Description
HU90 Patent valid on 900628